Ginkgo Bioworks Holdings, Inc. (DNA)

Market Cap	3.74B
Revenue (ttm)	325.95M
Net Income (ttm)	-1.22B
Shares Out	2.10B
EPS (ttm)	-0.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,501,258
Open	1.94
Previous Close	1.73
Day's Range	1.75 - 2.07
52-Week Range	1.12 - 3.52
Beta	1.17
Analysts	Hold
Price Target	4.08 (+129.21%)
Earnings Date	Nov 13, 2023

About DNA

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,292
• Stock Exchange: NYSE
• Ticker Symbol: DNA

Financial Performance

In 2022, DNA's revenue was $477.71 million, an increase of 52.21% compared to the previous year's $313.84 million. Losses were -$2.10 billion, 15.0% more than in 2021.

Analyst Forecast

According to 4 analysts, the average rating for DNA stock is "Hold." The 12-month stock price forecast is $4.08, which is an increase of 129.21% from the latest price.

Price Target

$4.08

(129.21% upside)

Analyst Consensus: Hold